Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Growth hormone |
| Evidence grade | Strong |
| Also known as | Egrifta, TH9507 |
| Mechanism | A stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1. |
| Key benefits | Clinically demonstrated visceral adipose tissue reduction (~15–18%) · Improved triglycerides in trial populations · Preliminary evidence for cognitive benefit in older adults |
| Side effects | Joint pain and swelling · Injection-site erythema · Insulin resistance · Peripheral oedema |
| Half-life | 26–38 minutes |
| Administration | Daily subcutaneous injection, abdomen |
| Dosing overview | Approved label dose is 2 mg once daily |
| Storage | Refrigerated; reconstitute immediately before use per label |
| Legal status | FDA-approved for a specific indication; other uses are off-label. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.